about
Characteristics and Outcome of Streptococcus pneumoniae Endocarditis in the XXI Century: A Systematic Review of 111 Cases (2000-2013)Community-acquired pneumonia during the first post-pandemic influenza season: a prospective, multicentre cohort study.Prognostic factors in left-sided endocarditis: results from the Andalusian multicenter cohortEffect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort studyImpact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.Q fever endocarditis in Spain. Clinical characteristics and outcome.Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?Left-sided infective endocarditis in patients with liver cirrhosis.Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation.Influence of early surgical treatment on the prognosis of left-sided infective endocarditis: a multicenter cohort study.Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis.Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study.[Enterococcal endocarditis: a multicenter study of 76 cases].Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.Letter by Almendro-Delia et al Regarding Article, "Association Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis: A Prospective Study From the International Collaboration on Endocarditis".Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score.Prognostic implications of a negative echocardiography in patients with infective endocarditis.A pragmatic approach for mortality prediction after surgery in infective endocarditis: Optimizing and refining EuroSCORE.Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis.Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for TreatingEnterococcus faecalisInfective Endocarditis2016 Expert consensus document on prevention, diagnosis and treatment of short-term peripheral venous catheter-related infections in adultsIn reply—What Is the Optimal Timing for Surgical Treatment of Infective Endocarditis?Streptococcus agalactiae left-sided infective endocarditis. Analysis of 27 cases from a multicentric cohortSurgical treatment for infective endocarditis in elderly patientsNumb chin syndrome: a warning sign of aggressive B-cell malignancyQ fever and fever of unknown origin. Are the chronic forms of these conditions preventable?Left endocarditis, changes in the new millenniumInfective endocarditis: New forms of the disease, new therapeutic optionsSequential antimicrobial therapy in mediastinitis after cardiac surgery: An observational study of 81 casesHigh delayed mortality after the first episode of Clostridium difficile infectionLeft-sided infective endocarditis caused by Streptococcus agalactiae: rare and serious
P50
Q26782968-F43C6450-5DBB-4B76-9B01-F815AEF2FE9CQ30431627-65CA985E-CCA4-4490-A1F2-DDED18CB38FBQ33526060-D4BF1099-7CA9-4508-B216-09991E3F731AQ35077842-BAE32B35-797E-49B7-8BFD-F18E4811CA37Q38127663-F1876265-8970-46DC-B718-A82992B9DFF4Q40333455-0E4C4B91-35F7-40BB-93C3-004F021D423FQ40891194-5F737656-D1AD-48A8-854C-78B8DB24F624Q40980929-1A81D079-D666-4965-A2B8-4492E6AACA68Q41490684-DA7E0FBC-9721-4E61-8076-2BFDE12046B4Q41758998-202AFBB0-1484-42B9-8E94-F47C56E8C1ACQ42214266-6F5C4DC3-D852-4F64-A729-EC8DF6456D91Q42264003-59FFE12E-8D75-4A12-B549-C435F0131915Q43576953-405CF2DD-0A57-4AD3-A2CE-80E5D2776C83Q47654438-94763249-58CE-4952-AFE4-96B99D0125ABQ48937508-D226D53A-C307-49C1-BD61-89F48731A045Q49913540-6A33D1B6-06A4-4934-99A1-155761CA12A9Q50154533-982E437B-5CFF-4890-B290-3270D177CA83Q50167807-08FA197C-57E6-4FAD-B568-28A903332F6AQ53823682-9D34CF93-3E7C-4377-83A7-24F79F769ED6Q56794090-707E068D-E81B-4ECA-B768-017C25B8FB07Q58405170-56D0EDB5-8DA7-414C-A68D-FF2A5801B90BQ59617319-4F03809D-266E-4886-BD5F-A038F5381515Q84106588-C5853ED0-DEA2-4A60-A361-0A21F3C5B80CQ84378053-4C7F26DB-3271-477D-802E-81818AED62EDQ84454871-1C6D3EBF-8E62-4884-872B-A1B4C0A73E3BQ87157083-16D9821C-0F22-43F1-AC0C-9DA816B32339Q88884830-199522E3-EDC0-47AE-B3D3-8F9262CB1D2DQ92168072-E7360469-94DE-4497-AC91-D9CB16539908Q92607205-0C673679-238E-448C-BB07-0D043DEDEBEBQ92931066-603C739A-8F13-4305-AB4B-C4DCABEC530CQ93085878-4304E8C5-A0E5-4F75-A448-F129E1826E40
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan Gálvez-Acebal
@ast
Juan Gálvez-Acebal
@en
Juan Gálvez-Acebal
@es
Juan Gálvez-Acebal
@nl
Juan Gálvez-Acebal
@sl
type
label
Juan Gálvez-Acebal
@ast
Juan Gálvez-Acebal
@en
Juan Gálvez-Acebal
@es
Juan Gálvez-Acebal
@nl
Juan Gálvez-Acebal
@sl
altLabel
Juan Galvez Aceval
@en
Juan Gálvez
@en
prefLabel
Juan Gálvez-Acebal
@ast
Juan Gálvez-Acebal
@en
Juan Gálvez-Acebal
@es
Juan Gálvez-Acebal
@nl
Juan Gálvez-Acebal
@sl
P1053
K-6462-2013
P106
P1153
7102941300
P21
P213
0000 0003 5516 9949
P31
P3829
P3835
juan-galvez-acebal2
P496
0000-0002-5294-4957